Rhabdomyosarcoma natural history, complications and prognosis: Difference between revisions
No edit summary |
|||
| Line 17: | Line 17: | ||
*** Visceral involvement | *** Visceral involvement | ||
*** brain metastases | *** brain metastases | ||
* Patients may develop with some complications after treatment such as:<ref name="pmid15700252">{{cite journal| author=Punyko JA, Mertens AC, Gurney JG, Yasui Y, Donaldson SS, Rodeberg DA et al.| title=Long-term medical effects of childhood and adolescent rhabdomyosarcoma: a report from the childhood cancer survivor study. | journal=Pediatr Blood Cancer | year= 2005 | volume= 44 | issue= 7 | pages= 643-53 | pmid=15700252 | doi=10.1002/pbc.20310 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15700252 }} </ref> | |||
** Cardiomyopathy | |||
*** Regarding anthracycline and cyclophosphamide use | |||
** Pulmonary failure | |||
** Renal electrolyte wasting | |||
*** Regarding ifosfamide use | |||
** Acute myelogenous leukemia | |||
*** Regarding etoposide use | |||
** Secondary malignancies | |||
*** Skin and bone tumors regarding radiotherapy | |||
==Prognosis== | ==Prognosis== | ||
Revision as of 16:06, 20 February 2019
|
Rhabdomyosarcoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Rhabdomyosarcoma natural history, complications and prognosis On the Web |
|
American Roentgen Ray Society Images of Rhabdomyosarcoma natural history, complications and prognosis |
|
FDA on Rhabdomyosarcoma natural history, complications and prognosis |
|
CDC on Rhabdomyosarcoma natural history, complications and prognosis |
|
Rhabdomyosarcoma natural history, complications and prognosis in the news |
|
Blogs on Rhabdomyosarcoma natural history, complications and prognosis |
|
Risk calculators and risk factors for Rhabdomyosarcoma natural history, complications and prognosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Shadan Mehraban, M.D.[2]
Overview
Common complications of rhabdomyosarcoma include metastasis to lung, bone marrow, and bone. Rhabdomyosarcoma is associated with a 5 year survival rate of 72%. The presence of metastasis is associated with a particularly poor prognosis. Histologically, the embryonal type rhabdomyosarcoma and anatomically, the orbital and genitourinary tract rhabdomyosarcomas have the most favorable prognosis.
Complications
- Rhabdomyosarcoma may cause metastasis to other organs.[1]
- Patients may develop with some complications after treatment such as:[5]
- Cardiomyopathy
- Regarding anthracycline and cyclophosphamide use
- Pulmonary failure
- Renal electrolyte wasting
- Regarding ifosfamide use
- Acute myelogenous leukemia
- Regarding etoposide use
- Secondary malignancies
- Skin and bone tumors regarding radiotherapy
- Cardiomyopathy
Prognosis
- Rhabdomyosarcoma is associated with a 5 year survival rate of 72%.
- The presence of metastasis is associated with a particularly poor prognosis among patients with rhabdomyosarcoma. The 5 year event free survival rate is less than 30%.
- Histologically, the embryonal type rhabdomyosarcoma and anatomically, the orbital and genitourinary tract rhabdomyosarcomas have the most favorable prognosis.
References
- ↑ Raney RB, Tefft M, Maurer HM, Ragab AH, Hays DM, Soule EH; et al. (1988). "Disease patterns and survival rate in children with metastatic soft-tissue sarcoma. A report from the Intergroup Rhabdomyosarcoma Study (IRS)-I". Cancer. 62 (7): 1257–66. PMID 2843274.
- ↑ Koscielniak E, Rodary C, Flamant F, Carli M, Treuner J, Pinkerton CR; et al. (1992). "Metastatic rhabdomyosarcoma and histologically similar tumors in childhood: a retrospective European multi-center analysis". Med Pediatr Oncol. 20 (3): 209–14. PMID 1574030.
- ↑ Ruymann FB, Newton WA, Ragab AH, Donaldson MH, Foulkes M (1984). "Bone marrow metastases at diagnosis in children and adolescents with rhabdomyosarcoma. A report from the intergroup rhabdomyosarcoma study". Cancer. 53 (2): 368–73. PMID 6546301.
- ↑ Breneman JC, Lyden E, Pappo AS, Link MP, Anderson JR, Parham DM; et al. (2003). "Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma--a report from the Intergroup Rhabdomyosarcoma Study IV". J Clin Oncol. 21 (1): 78–84. doi:10.1200/JCO.2003.06.129. PMID 12506174.
- ↑ Punyko JA, Mertens AC, Gurney JG, Yasui Y, Donaldson SS, Rodeberg DA; et al. (2005). "Long-term medical effects of childhood and adolescent rhabdomyosarcoma: a report from the childhood cancer survivor study". Pediatr Blood Cancer. 44 (7): 643–53. doi:10.1002/pbc.20310. PMID 15700252.